CDT enters consulting pacts with Thesprogen and NJS; issues 213,288 shares for $305k in services

CDT Equity Inc.

Thesprogen will evaluate AZD1656 pre-clinical data and optimize development strategies; 6-month term, $155k fee paid in 108,392 shares.
NJS to identify out-licensing partners for solid-form patent portfolio; $150k retainer in 104,896 shares plus 8% commission on transactions.
Shares issued in unregistered transaction under Regulation D; no registration rights granted.
Press release highlights NJS engagement to accelerate licensing and royalty-based deals for solid-form assets.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CDT Equity Inc. entered into Thesprogen Agreement with Thesprogen, PC valued at $155,000 of consideration (effective 2025-12-28).

Action: entry
Counterparty: Thesprogen, PC
Value: $155,000 of consideration
Effective: 2025-12-28

Exact text from the filing

On December 28, 2025, CDT Equity, Inc. (the “Company” or “CDT”) and Thesprogen, PC (“Thesprogen”) entered into a Consulting Agreement (the “Thesprogen Agreement”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CDT Equity Inc. entered into NJS Agreement with NJS Foresight Bio-Advisory, LLC valued at one-time fixed retainer of $150,000 (effective 2025-12-29).

Action: entry
Counterparty: NJS Foresight Bio-Advisory, LLC
Value: one-time fixed retainer of $150,000
Effective: 2025-12-29

Exact text from the filing

On December 29, 2025 (the “Effective Date”) the Company and NJS Foresight Bio-Advisory, LLC (“NJS”) entered into a Consulting Agreement (the “NJS Agreement,” together with the Thesprogen Agreement, the “Agreements”)

View on SEC.gov

119 material agreements filed in the last 30 days. Browse all material agreements →

CDT Equity Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-000143

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.